Home testing kits, coordinated outreach improve CRC screening rates

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

The web page for the FDA Office of Minority Health and Health Equity is no more.

February 07, 2025

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath

When Marsha B. Henderson, former FDA Associate Commissioner of Women’s Health (1998-2019), sat down for an oral history interview upon her retirement from the agency, she could not have foreseen becoming party to a government digital purge 7 years later. Over the past week, the Trump administration has been busy at work deleting government webpages...

COA proposes health care reform blueprint

The Community Oncology Alliance released the COA Prescription for Health Care Reform, a blueprint that diagnoses the fundamental challenges facing the U.S. healthcare system, outlines the consequences for patients across America, and presents “actionable solutions .”

February 07, 2025

Vol.51 No.05

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.

January 31, 2025

Vol.51 No.04

By Yiqing Wang and Jacquelyn Cobb

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04

Clinical Roundup

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

January 31, 2025

Vol.51 No.04

Home testing kits, coordinated outreach improve CRC screening rates

YOU MAY BE INTERESTED IN

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath

COA proposes health care reform blueprint

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login

Home testing kits, coordinated outreach improve CRC screening rates

YOU MAY BE INTERESTED IN

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and genderMedical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”Preserving an oral history by the former FDA associate commissioner of women’s heath

COA proposes health care reform blueprint

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Never miss an issue!

Login

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath